Indication

Transthyretin familial amyloid polyneuropathy

Transthyretin familial amyloid polyneuropathy is a rare, life-threatening, autosomal dominant hereditary disorder caused by pathogenic mutations in the transthyretin (*TTR*) gene. Read more about Transthyretin familial amyloid polyneuropathy

4 drugs 3 manufacturers

Advertisement

Drugs that treat it

Common Transthyretin familial amyloid polyneuropathy therapies.

Showing 1–4 of 4 drugs

TEGSEDI (inotersen sodium)

AMYLOIDOSIS AGENTS - TRANSTHYRETIN (TTR) SUPPRESSION·TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY
AKCEA THERAPEUT

AMVUTTRA (vutrisiran sodium)

AMYLOIDOSIS AGENTS - TRANSTHYRETIN (TTR) SUPPRESSION·TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY·+1
ALNYLAM PHARMAC

WAINUA (eplontersen sodium)

AMYLOIDOSIS AGENTS - TRANSTHYRETIN (TTR) SUPPRESSION·TRANSTHYRETIN FAMILIAL AMYLOID POLYNEUROPATHY
AstraZeneca Pharmaceuticals
Filter & compare in the drug finder →Opens the drug finder with Transthyretin familial amyloid polyneuropathy preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Transthyretin familial amyloid polyneuropathy.

Transthyretin familial amyloid polyneuropathy is a rare, life-threatening, autosomal dominant hereditary disorder caused by pathogenic mutations in the transthyretin (*TTR*) gene.

It primarily affects the peripheral and autonomic nervous systems of adults, frequently involving the cardiovascular system and other organs.

Pathophysiologically, the genetic variant destabilizes the hepatic transthyretin tetramer, causing misfolded protein monomers to aggregate and deposit extracellularly as insoluble amyloid fibrils within the endoneurium and other tissues.

Clinically, it is characterized by a progressive, length-dependent sensorimotor polyneuropathy—typically starting with small-fiber sensory deficits and weakness in the lower extremities—accompanied by severe dysautonomia, such as gastrointestinal dysmotility and orthostatic hypotension.

Personalize your experience

Follow Transthyretin familial amyloid polyneuropathy and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it